TNXP.NASDAQTonix Pharmaceuticals Holding CORP
8-K: Tonix Pharmaceuticals Announces First Quarter 2025 Financial Results and Operational Highlights
Sentiment:
Quarterly Report
Tonix Pharmaceuticals reported its Q1 2025 financial results, highlighting progress with TNX-102 SL for fibromyalgia and a cash runway into Q2 2026.
Delay expectedThe Company discontinued enrollment and terminated the Phase 2 CATALYST study of its TNX-1300 double-mutant cocaine esterase 200 mg, i.v. solution product candidate for the treatment of cocaine intoxication because enrollment in this emergency department-based study was slower than projected.
Capital raiseThe Company entered into a Sales Agreement with AGP pursuant to which the Company may issue and sell, from time to time, shares of the Company's common stock having an aggregate offering price of up to $250.0 million in at-the-market sales.During the three months ended March 31, 2025, the Company sold approximately 2.7 million shares of common stock for net proceeds of approximately $59.8 million.Subsequent to March 31, 2025, the Company sold 0.6 million shares of common stock under the Sales Agreement, for net proceeds of approximately $9.9 million.
Summary
- Tonix Pharmaceuticals announced its first quarter 2025 financial results and provided an overview of recent operational highlights.
- The company's key focus remains on the FDA's PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia.
- If approved, TNX-102 SL would be the first new drug for treating fibromyalgia in more than 15 years.
- Tonix reported positive topline results from a Phase 1 study of TNX-1500, a next-generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune disorders.
- As of March 31, 2025, Tonix had $131.7 million in cash and cash equivalents, which is expected to fund operations into the second quarter of 2026.
- Net product revenue for the first quarter 2025 was approximately $2.4 million, compared to $2.5 million for the same period in 2024.
- Research and development expenses for the first quarter 2025 were $7.4 million, compared to $12.9 million for the same period in 2024.
- Net loss available to common stockholders was $16.8 million, or $2.84 per share, for the first quarter 2025, compared to a net loss of $14.9 million, or $535.72 per share, for the same period in 2024.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the progress with TNX-102 SL, positive Phase 1 results for TNX-1500, and a sufficient cash runway. However, the net loss and discontinuation of the TNX-1300 study temper the overall sentiment.
Positives
- TNX-102 SL is on track to potentially become a new therapeutic option for fibromyalgia patients, with a PDUFA goal date of August 15, 2025.
- Positive Phase 1 results for TNX-1500 support further development for kidney transplant rejection and autoimmune diseases.
- The company's cash position of $131.7 million as of March 31, 2025, is expected to fund operations into the second quarter of 2026.
- FDA will not require an Advisory Committee meeting to discuss the Company's New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia.
- The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need.
Negatives
- Net loss available to common stockholders was $16.8 million for the first quarter 2025.
- The Company discontinued enrollment and terminated the Phase 2 CATALYST study of its TNX-1300 double-mutant cocaine esterase 200 mg, i.v. solution product candidate for the treatment of cocaine intoxication because enrollment in this emergency department-based study was slower than projected.
Risks
- The company's success is heavily reliant on the FDA's approval of TNX-102 SL.
- Clinical development of product candidates carries significant risks and uncertainties.
- The company may require additional financing in the future.
- The company faces substantial competition in the pharmaceutical industry.
Future Outlook
Tonix believes its cash resources at March 31, 2025, along with the net proceeds of $9.9 million raised from equity offerings in the second quarter of 2025, will meet its planned operating and capital expenditure requirements into the second quarter of 2026.
Management Comments
- We believe TNX-102 SL (cyclobenzaprine HCl sublingual tablets)* is on track to become a new therapeutic option for patients suffering with fibromyalgia, said Seth Lederman, M.D., Chief Executive Officer of Tonix.
- Beyond TNX-102 SL for fibromyalgia, we are encouraged by the continued achievements in our pipeline, including positive Phase 1 results for TNX-1500, a next generation anti-CD40L Fc-modified humanized monoclonal antibody (mAb) in development for prevention of kidney transplant rejection and pre-clinical results for TNX-801, a live-virus vaccine in development for preventing mpox and smallpox.
Industry Context
Tonix is operating in the competitive biopharmaceutical industry, focusing on pain management and vaccines. The potential approval of TNX-102 SL could provide a significant advantage in the fibromyalgia treatment market, which has seen limited innovation in recent years. The development of TNX-1500 and TNX-801 also positions the company to address critical needs in organ transplantation, autoimmune diseases, and infectious disease prevention.
Comparison to Industry Standards
- The development of TNX-1500, an anti-CD40L monoclonal antibody, places Tonix in competition with companies like Bristol Myers Squibb, which has also explored CD40L inhibition for autoimmune diseases.
- The TNX-801 vaccine for mpox and smallpox is competing in a market with established players like Bavarian Nordic, which produces the Jynneos vaccine.
- Tonix's focus on fibromyalgia with TNX-102 SL puts it in a space with companies like Eli Lilly (Cymbalta) and Pfizer (Lyrica), though TNX-102 SL aims to be a first-in-class tertiary amine tricyclic (TAT) non-opioid analgesic.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Technical Officer | NA | Siobhan Fogarty | During the first quarter of 2025 | Promotion |
| Vice President, Market Access | NA | Gary Ainsworth | During the first quarter of 2025 | Appointment |
Stakeholder Impact
- Shareholders: The company's financial performance and pipeline progress will impact shareholder value.
- Patients: The potential approval of TNX-102 SL could provide a new treatment option for fibromyalgia patients.
- Employees: The company's financial stability and pipeline progress impact job security and opportunities.
- Customers: The launch of TONIX ONE aims to improve the patient experience for migraine sufferers.
Next Steps
- Focus on the FDA's decision regarding TNX-102 SL by the PDUFA goal date of August 15, 2025.
- Build out the commercial team for the anticipated product launch of TNX-102 SL in the fourth quarter of this year.
- Continue development of TNX-1500, including planning for a Phase 2 trial in kidney transplant recipients.
- Advance the development of TNX-801 as a vaccine for mpox and smallpox.
- Evaluate new study designs and new endpoints for further development of TNX-1300.
Key Dates
| Date | Description |
|---|---|
| 2024 | FDA granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. |
| 2024-07-30 | The Company entered into a Sales Agreement with AGP pursuant to which the Company may issue and sell, from time to time, shares of the Company's common stock having an aggregate offering price of up to $250.0 million in at-the-market sales. |
| 2024-09 | Tonix announced that the WHO's preferred target product profile (TPP), released at the WHO sponsored Mpox Research and Innovation Scientific Conference, aligns with the characteristics of TNX-801. |
| 2024-12 | The NDA for TNX-102 SL for fibromyalgia was accepted by FDA with a PDUFA goal date of August 15, 2025. |
| 2025-02 | Tonix announced positive topline results from its Phase 1, single ascending dose (SAD) first-in-human trial of TNX-1500 in healthy participants. |
| 2025-03 | Tonix announced that FDA will not require an Advisory Committee meeting to discuss the Company's New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia. |
| 2025-03 | Tonix announced it was awarded a grant from the Medical CBRN Defense Consortium (MCDC) to support the development of TNX-801. |
| 2025-03-31 | Tonix had $131.7 million of cash and cash equivalents. |
| 2025-04 | Tonix presented data and analyses of TNX-102 SL treatment and effects on fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting. |
| 2025-04 | Tonix presented data on TNX-801 in an oral presentation at the World Vaccine Congress Washington 2025, held in Washington, D.C. |
| 2025-04 | The Company announced it has entered into a collaborative research agreement with Makana Therapeutics to study Tonix's anti-CD40L monoclonal antibody candidate, TNX-1500, in combination with Makana's human-compatible pig organs and cells for the treatment of organ failure. |
| 2025-04 | Tonix announced the launch of TONIX ONE, a fully-integrated digital platform designed to provide resources to help patients better understand and manage their migraine condition. |
| 2025-05-12 | Date of report (date of earliest event reported). |
| 2025-08-15 | FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia. |
Keywords
TNX-102 SL, fibromyalgia, TNX-1500, kidney transplant, autoimmune disorders, TNX-801, mpox, smallpox, financial results, biopharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.